ASMB:NSD-Assembly Biosciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.21

Change

+0.27 (+4.55)%

Market Cap

USD 0.20B

Volume

1.10M

Average Target Price

USD 11.50 (+85.19%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.74 (-3.01%)

USD62.38B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.45 (+0.64%)

USD58.99B 22.23 17.39
REGN Regeneron Pharmaceuticals, Inc

-6.39 (-1.28%)

USD53.23B 18.28 14.53
SGEN Seagen Inc

-0.93 (-0.52%)

USD32.25B 68.04 62.62
BNTX BioNTech SE

+1.32 (+1.11%)

USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.55 (-0.45%)

USD26.49B 28.09 26.92
RPRX Royalty Pharma plc

+0.68 (+1.61%)

USD26.44B 22.60 9.98
GMAB Genmab A/S

+0.10 (+0.26%)

USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

+1.57 (+0.71%)

USD20.63B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ASMB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -69.65% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.65% 5% F 2% F
Trailing 12 Months  
Capital Gain -62.20% 8% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.20% 8% F 3% F
Trailing 5 Years  
Capital Gain -26.77% 51% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.77% 51% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 79.17% N/A N/A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.17% N/A N/A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 135.57% N/A N/A 6% F
Risk Adjusted Return 58.40% N/A N/A 77% C+
Market Capitalization 0.20B 41% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.73 98% A+ 92% A-
Price / Cash Flow Ratio -2.33 26% F 65% D
EV/EBITDA 0.54 50% F 92% A-
Management Effectiveness  
Return on Equity -23.33% 85% B 33% F
Return on Invested Capital -42.13% 70% C- 22% F
Return on Assets -12.30% 82% B- 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.63 72% C- 69% D+
Short Percent 9.00% 35% F 24% F
Beta 0.66 84% B 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector